Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1080/09546634.2020.1789051 http://scihub22266oqcxt.onion/10.1080/09546634.2020.1789051 32598204!?!32598204 Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32598204&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       J+Dermatolog+Treat 2022 ; 33 (2): 699-703 Nephropedia Template TP {{tp|p=32598204|t=2022. COVID-19 and psoriasis: biologic treatment and challenges |pdf=|usr=}}{{32598204}} gab.com Text COVID-19 and psoriasis: biologic treatment and challenges JO: J Dermatolog Treat http://www.kidney.de/pget.php?&tw=1&pmid=32598204 #FOAvip BACKGROUND: There is concern about susceptibility of psoriatic patients on biologics to coronavirus disease 2019 (COVID-19) and its clinical course. PURPOSE: The aims of present review were to determine whether the biologic treatment of psoriasis increases the risk of SARS-CoV-2 infection and if biologics affect the clinical course of COVID-19 in these patients. METHODS: We searched database of MEDLINE (PubMed) for key term of psoriasis biologic and COVID-19 until June 9, 2020 and all published 14 papers and an experience from Iran (10509 cases) related to the psoriatic patients on biologics and COVID-19 along with relevant papers were summarized. In spite of limitation in some reports, due to some of strengths that will be discussed, all papers were included in this review. RESULTS: According to 8769 medical reports around 0.3% of psoriatic patients had COVID-19 and the rate of hospitalization was 0.1%. No death due to COVID-19 was reported among 10509 patients. Reports indicated psoriatic patients on biologics were not more susceptible to COVID-19 and the severe clinical course of disease. CONCLUSION: While there is not definitive controlled trial data, the available evidence suggests that patients with psoriasis without COVID-19 can continue the biologic therapy for psoriasis. Twit Text FOAVip COVID-19 and psoriasis: biologic treatment and challenges ????J Dermatolog Treat http://www.kidney.de/pget.php?&tw=1&pmid=32598204 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32598204 #FOAvip English Wikipedia <ref>{{Cite pmid|32598204}}</ref> COVID-19 and psoriasis: biologic treatment and challenges #MMPMID32598204 Ebrahimi A; Sayad B; Rahimi Z J Dermatolog Treat 2022[Mar]; 33 (2): 699-703 PMID32598204show ga BACKGROUND: There is concern about susceptibility of psoriatic patients on biologics to coronavirus disease 2019 (COVID-19) and its clinical course. PURPOSE: The aims of present review were to determine whether the biologic treatment of psoriasis increases the risk of SARS-CoV-2 infection and if biologics affect the clinical course of COVID-19 in these patients. METHODS: We searched database of MEDLINE (PubMed) for key term of psoriasis biologic and COVID-19 until June 9, 2020 and all published 14 papers and an experience from Iran (10509 cases) related to the psoriatic patients on biologics and COVID-19 along with relevant papers were summarized. In spite of limitation in some reports, due to some of strengths that will be discussed, all papers were included in this review. RESULTS: According to 8769 medical reports around 0.3% of psoriatic patients had COVID-19 and the rate of hospitalization was 0.1%. No death due to COVID-19 was reported among 10509 patients. Reports indicated psoriatic patients on biologics were not more susceptible to COVID-19 and the severe clinical course of disease. CONCLUSION: While there is not definitive controlled trial data, the available evidence suggests that patients with psoriasis without COVID-19 can continue the biologic therapy for psoriasis. |*Biological Products/therapeutic use[MESH] |*COVID-19[MESH] |*Psoriasis/drug therapy[MESH] |Biological Therapy[MESH] |Humans[MESH]COVID-19 and psoriasis: biologic treatment and challenges (epmc).pdf DeepDyve Pubget Overpricing